Mr Shortie
20 Apr 2018
Allergan confirmed will not bid
chopper89x
19 Apr 2018
Bidding war allergan now in the frame and cofirmedwait till pfizer show their superior cash offer
DaveHughes
19 Apr 2018
Re: Re: "one would assume that £46.5 was their opening shot."Apparently, it is the third shot.... it may be the first serious one though![link]
gamesinvestor
19 Apr 2018
Re: rejected and talks continue - one would assume that £46.5 was their opening shot.It's got to be £50 they have been thinking of as a settlement - assuming SHP management would recommend to shareholders at £50.As the bid has only just come in, maybe there will be other interested parties by tomorrow?Quite a few days before the 25th, so anything could happen here. Shame the share price was already so ridiculously low before this all started - but I guess that was the catalyst.Games
Baker2005
19 Apr 2018
Re: £46.50 more here. [link] that offer was made on 12th, and that Shire have rejected. But at least it means the game is on ( at least until 25th anyway)
axolotl
19 Apr 2018
Re: £46.50 Is this likely to be a final 'agreed' offer? Or is it more likely to end up higher?
sound money
19 Apr 2018
£46.50 LONDON (Reuters) - Takeda Pharmaceutical (>> Takeda Pharmaceutical Co Ltd) has made a bid for Shire (>> Shire) that values the London-listed drugmaker at around $61 billion, two sources with direct knowledge of the matter told Reuters.LONDON (Reuters) - Takeda Pharmaceutical has made a bid for Shire that values the London-listed drugmaker at around $61 billion, two sources with direct knowledge of the matter told Reuters.The Japanese company's indicative cash-and-stock takeover proposal is worth about 46.50 pounds per share, the sources said.The moves comes ahead of an April 25 deadline for Takeda to make a firm offer or walk away from the FTSE 100 company. Shares in Shire were up 6.3 percent at 39.90 pounds at 1113 GMT in London.Takeda confirmed last month it was considering an offer for Shire, which sells treatments for rare diseases and attention deficit disorder.A takeover would be transformational for Takeda, which has a market value of about $37.8 billion, making it smaller than its bid target.Its bid values Shire at approximately 43 billion pounds, or $61 billion, Thomson Reuters data showed.A spokesman for Takeda declined to comment and Shire did not reply to a request for comment.The bid comes amid a surge in mergers and acquisitions (M&A) in the UK as companies take advantage of cheap debt to pursue dealmaking opportunities.The value of M&A involving British firms rose by 56.5 percent to $164.3 billion in the first three months of the year, the most since 2007, Thomson Reuters data show
Baker2005
19 Apr 2018
Re: offer - what price per share? Reports of an offer made £46.50, but no confirmation yet[link]
axolotl
19 Apr 2018
offer - what price per share? Can anyone give a well-researched estimate of how much will have to be paid per SHP share for a takeover?
tikky
18 Apr 2018
back up again hope some encouraging news up over 100 p waiting for the real bid 24th date closer nowwill take profits soonincase th bid drop outnote over 200 dmaimho
axolotl
16 Apr 2018
Re: Sale of Oncology Division "To be honest I'd rather the Japanese company just go away and leave SHP to grow it's business, pay down some of it's debt and keep going.Games"I agree
gamesinvestor
16 Apr 2018
Re: Sale of Oncology Division Prov -- If he sold the company for 9.2X sales similar to the oncology division, that would value the company at a tad more -- not realistic I assume?But then again why not -- if the statement is true that the more valuable part of the business is rare diseases and this is one of the chunky parts of the business, then a considerable portion of the company could (should) be worth more than 9.2X sales.£50 seems too low in many respects.Reminds me of the old days when (not so old actually - 2010) when Cadbury sold out to Kraft for $12bn -- during that time Dr Peppar was almost thrown away as an insignificant part of Cadbury.This year Dr Peppar was sold for $15BN -- where would that realistically have valued a brand like Cadbury?To be honest I'd rather the Japanese company just go away and leave SHP to grow it's business, pay down some of it's debt and keep going.Games
Proverbs 26 vs 5
16 Apr 2018
Re: Sale of Oncology Division My opinion for what it's worth (probably not very much) is that any bid now would have to be north of £50/share to be acceptable.
gamesinvestor
16 Apr 2018
Sale of Oncology Division [link] in cash for a revenue of $262M -- sounds like a good price at approx 9.2X revenue.Not sure what that multiple was in terms of profit, it doesn't disclose that detail.The supposed bid by Takeda of £35bn doesn't seem much of a premium to it's current £33.5Bn market cap and it's likely to be rejected no?Games
Neil J Stanley
12 Apr 2018
Takeda sounds out banks for loans as it moves towards Shire bid. Takeda sounds out banks for loans as it moves towards Shire bid.[link]
